Evolent Health EVH 深 沪
等待开盘 07-18 09:30:00 美东时间
11.27
-0.170
-1.49%
华盛通- 最 高11.81
- 今 开11.71
- 成交量 202.01万股
- 最 低 11.23
- 昨 收 11.44
- 总市值 13.19亿
- 52周最高 33.63
- 市盈率 静 --
- 换手率 1.73%
- 52周最低 7.06
- 委 比 50.30%
- 总股本 1.17亿
- 历史最高 39.779
- 量 比 1.28
- 振 幅 5.07%
- 历史最低 3.50
- 每 手 1
- 风险率 7.87%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The Analyst Verdict: Evolent Health In The Eyes Of 5 Experts
In the last three months, 5 analysts have published ratings on Evolent Health (...
今天 06:00
Truist Securities Maintains Buy on Evolent Health, Raises Price Target to $16
Truist Securities analyst Jailendra Singh maintains Evolent Health (NYSE:EVH) with a Buy and raises the price target from $14 to $16.
07-17 22:37
Evolent Health taps David Lim as chief clinical officer
Evolent Health (NYSE:EVH) has appointed David Lim as chief clinical officer to lead its 300-person medical team. Before joining Evolent, Lim served as chief medical officer of virtual physical therapy...
07-09 20:21
Evolent announces key appointments to leadership team
Dr. David Lim joins Evolent as chief clinical officer John Way joins Evolent as CFO, Performance Suite WASHINGTON, July 9, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company fo...
07-09 20:00
特朗普“大而美”法案 谁受伤 谁受益？
“大而美”减税法案通过，延长减税并增加国防和边境预算，但削减医疗补助和可再生能源支持，引发争议。法案预计使债务增加4.1万亿美元，1180万人失去医保，选民反对率为50%。医疗补助削减影响保险公司收入，对可再生能源行业造成重创，取消税收抵免和多项清洁能源政策。法案为企业减税，刺激制造业投资，特别针对半导体行业，但 lowest收入群体实际收入下降1.1%，中产家庭收入增加1.8%。
07-04 14:10
美股大行评级 | 潜在涨幅378.93%！aTyr Pharma获富国银行升目标价至25美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1143101010774646784.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 富国银行：维持aTyr Pharma(ATYR)"超配"评级，目标价从17美元升至25美元</p> <p>• 摩根大通：维持Array Technologies(ARRY)"超配"评级，目标价从12美元升至13美元</p>
06-21 08:35
Demystifying Evolent Health: Insights From 5 Analyst Reviews
Evolent Health (NYSE:EVH) underwent analysis by 5 analysts in the last quarter,...
06-20 22:00
JMP Securities Reiterates Market Outperform on Evolent Health, Maintains $13 Price Target
JMP Securities analyst Constantine Davides reiterates Evolent Health (NYSE:EVH) with a Market Outperform and maintains $13 price target.
06-20 21:33
Evolent Health Reiterated Q2 Adj EBITDA Of $33M-$40M And Fiscal Adj EBITDA Of $135M-$165M
Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that based on leading indicators and paid claims data through May, it continues
06-20 18:33
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA
Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON, June 20, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on ...
06-20 18:30
